YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The United States market has recently seen a 1.2% increase over the past week and an impressive 27% rise over the last year, with earnings expected to grow by 17% annually. In this thriving environment, identifying high-growth tech stocks…
The United States market has shown robust performance recently, with a 1.2% increase over the past week and a substantial 29% rise over the last year, while earnings are projected to grow by 17% annually. In this environment, identifying h…
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. Thi…
Over the last 7 days, the United States market has risen by 1.1% and is up 27% over the past year, with earnings forecasted to grow by 17% annually. In this favorable environment, identifying high growth tech stocks involves looking for co…
The United States market has experienced a 1.5% increase over the last week and a substantial 26% rise over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks i…
Over the last 7 days, the United States market has risen by 2.2% and is up 31% over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this favorable environment, identifying high growth tech stocks in…
The United States market has shown a robust performance, climbing 3.2% in the last week and up 31% over the past year, with earnings forecasted to grow by 16% annually. In such a dynamic environment, identifying high growth tech stocks inv…
The United States market has remained flat over the last week, yet it has shown a robust 28% increase over the past year with earnings expected to grow by 16% annually. In such an environment, identifying high growth tech stocks that align…
In the last week, the United States market has stayed flat, yet it has experienced a significant rise of 28% over the past 12 months, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth pot…
The United States market has shown a mixed performance recently, remaining flat over the last week but achieving a substantial 29% increase over the past year with earnings projected to grow by 16% annually. In this context, identifying hi…
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth expectations, identifying h…
The United States market has remained flat over the last week but is up 30% over the past year, with earnings forecast to grow by 16% annually. In this environment, identifying high-growth tech stocks that demonstrate strong potential for…
The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech…
The United States market has remained flat over the past week but has experienced a significant 30% increase over the past year, with earnings projected to grow by 16% annually. In this context, identifying high growth tech stocks involves…
The United States market has shown robust performance with a 1.7% increase over the last week and a remarkable 34% rise over the past year, while earnings are anticipated to grow by 16% annually in the coming years. In this thriving enviro…
The United States market has shown robust performance recently, climbing 1.9% in the last week and achieving a remarkable 24% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In such a dynam…
Over the last 7 days, the United States market has remained flat, but it is up 16% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks involve…
Over the last 7 days, the United States market has dropped 3.5%, yet it has seen a rise of 14% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves l…
Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has seen a significant 15% rise over the past year, with earnings expected to grow by 16% annually. In this context of fluctuating market conditions and pro…
The United States market remained flat over the last week but has risen 16% over the past year, with earnings projected to grow by 16% annually in the coming years. In light of these conditions, identifying high growth tech stocks involves…
Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings expected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companie…
Marker Therapeutics’ MRKR shares have surged approximately 114% over the past three months, driven by strong momentum surrounding its early-stage lead candidate, MT-601, which has boosted investor confidence. Marker, a Texas-based cancer b…
As the U.S. market grapples with heightened geopolitical tensions and the threat of new tariffs, major indices like the Nasdaq and S&P 500 have experienced significant declines, reflecting broader market unease. Amidst this volatility, inv…
As the U.S. market grapples with rising Treasury yields and uncertainty surrounding Federal Reserve policies, major indexes have posted weekly losses, reflecting a cautious sentiment among investors. In this environment, identifying high g…
For Immediate Release Chicago, IL – January 8, 2026 – Today, Zacks Equity Research discusses Soleno Therapeutics SLNO, Nektar Therapeutics NKTR, Rigel Pharmaceuticals RIGL, Ironwood Pharmaceuticals IRWD and Marker Therapeutics MRKR. Indust…
After a sluggish first half, the drug and biotech sector has staged a recovery over the past two to three months. This rebound was supported by major drugmakers signing drug pricing agreements with the Trump administration, which eased con…
As 2026 begins, the U.S. stock market is showing signs of optimism with major indexes like the Dow and S&P 500 snapping recent losing streaks, although the Nasdaq continues to face challenges. In this environment of mixed signals and evolv…
(RTTNews) - Several small-cap biotech and healthcare names posted notable gains in Thursday's after-hours trading session, with investors reacting to recent corporate updates and clinical milestones. Inspira Technologies Oxy B.H.N. Ltd. (I…
As the United States market navigates a period of volatility, with major indexes closing lower amid concerns over an AI bubble and looming economic reports, investors are keenly observing the tech sector's dynamics. In such a climate, iden…
The United States market has recently experienced declines in major stock indexes, with technology shares exerting downward pressure on the Nasdaq amid concerns about an AI bubble. In this environment, identifying high-growth tech stocks i…
The U.S. stock market has recently experienced a surge, with major indices like the S&P 500 and the small-cap Russell 2000 reaching near-record highs following the Federal Reserve's decision to cut interest rates. This favorable monetary p…
As the U.S. stock market navigates a week marked by anticipation of the Federal Reserve's interest rate decision, major indices such as the S&P 500 have recently pulled back from record highs, reflecting investor caution amidst economic un…
* Marker Therapeutics press release [https://seekingalpha.com/pr/20307922-marker-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business] (MRKR [https://seekingalpha.com/symbol/MRKR]): Q3 GAAP EPS of -$0.12 beats by…
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patient…
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignanci…
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector…